Alexandra P. Zorzi, M. Bernstein, Y. Samson
Nov 1, 2013
Citations
0
Influential Citations
35
Citations
Journal
Pediatric Blood & Cancer
Abstract
Pracinostat (SB939) is a potent oral inhibitor of class 1, 2, and 4 histone deacetylases (HDAC). The adult recommended phase II dose (RP2D) is 60 mg po three times per week (t.i.w.) for 3 weeks every 4 weeks. This study assessed the toxicities and pharmacokinetics of pracinostat and determined the RP2D in children with refractory solid tumors.